drugset / Trial / NCT00692939

Autologous Stem Cell Transplantation for Crohn's Disease

NCT00692939

Phase 1/2 Recruiting 20 enrolled Paul Szabolcs
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.

Timeline

Start
2012-06-26
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous CD34-selected peripheral blood stem cells transplant Cell therapy
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule
Background ATG Unknown
Background Alemtuzumab Monoclonal antibody
Background Cyclophosphamide Other / unclassified
Background G-CSF Unknown
Background Melphalan Small molecule
Background Rituximab Monoclonal antibody
Background Thiotepa Other / unclassified

Indications